5 Key Takeaways

• 1

  Researchers developed R8L-NI@Lipo, a tumor-targeted lipoplex designed to generate CAR-expressing T cells and NK cells within solid tumors.

• 2

  The lipoplex delivers plasmid DNA encoding an NKG2D-based CAR and IL-15, with hypoxia-responsive elements designed to limit CAR expression to low-oxygen tumor environments.

• 3

  In mouse models, the targeted lipoplexes accumulated in tumors and penetrated beyond tumor blood vessels, while CAR expression was higher under hypoxic conditions.

• 4

  In the 4T1 model, treatment increased CD8+ T-cell infiltration 3.33-fold versus untreated controls, reduced mean tumor weight to about 9.2% of control, and produced complete regression in 2 of 6 mice.

• 5

  Median survival increased from 22.5 to 42.5 days in the 4T1 model and from 22.5 to 44.5 days in the EMT6 model; safety findings suggested reduced off-target effects with hypoxia-responsive regulation.